Biotechnology

BIORA THERAPEUTICS INC

BIORA THERAPEUTICS INC released FY2023 Q3 earnings on November 14 After-Market (EST), actual revenue 0 USD (forecast 500 USD), actual EPS -48.8887 USD

BIORA THERAPEUTICS INC released FY2023 9 Months Earnings on November 14 After-Market (EST), with actual revenue of 4 K USD and EPS of -79.4887 USD

BIORA THERAPEUTICS INC released FY2024 Q3 earnings on November 14 After-Market (EST), actual revenue 32 K USD (forecast 210 K USD), actual EPS -5.0376 USD

BIORA THERAPEUTICS INC released FY2024 9 Months Earnings on November 14 After-Market (EST), with actual revenue of 892 K USD and EPS of -6.8217 USD

BIORA THERAPEUTICS INC released FY2023 Q2 earnings on August 12 After-Market (EST), actual revenue 2 K USD (forecast 20 K USD), actual EPS -14.7 USD

BIORA THERAPEUTICS INC released FY2023 Semi-Annual Earnings on August 12 After-Market (EST), with actual revenue of 4 K USD and EPS of -30.0999 USD

BIORA THERAPEUTICS INC released FY2024 Semi-Annual Earnings on August 12 After-Market (EST), with actual revenue of 860K USD and EPS of -0.6412 USD

BIORA THERAPEUTICS INC released FY2024 Q2 earnings on August 12 After-Market (EST), actual revenue 318 K USD, actual EPS -0.3542 USD

BIORA THERAPEUTICS INC released FY2024 Q1 earnings on May 15 After-Market (EST), actual revenue 542 K USD, actual EPS -1.4298 USD

BIORA THERAPEUTICS INC released FY2023 Q1 earnings on May 15 After-Market (EST), actual revenue 2K USD, actual EPS -15.8999 USD

BIORA THERAPEUTICS INC released FY2022 Annual Earnings on April 1 After-Market (EST), actual revenue 305 K USD (forecast 300 K USD), actual EPS -49.9757 USD

BIORA THERAPEUTICS INC released FY2022 Q4 earnings on April 1 After-Market (EST), actual revenue 14 K USD (forecast 55 K USD), actual EPS -16.4536 USD

BIORA THERAPEUTICS INC released FY2023 annual earnings on April 1 After-Market (EST), actual revenue 4 K USD (forecast 2.5 K USD), actual EPS -78.6867 USD

BIORA THERAPEUTICS INC released FY2023 Q4 earnings on April 1 After-Market (EST), actual revenue 0 USD (forecast 500 USD), actual EPS -6.2121 USD

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

阿里拉姆制药

Argenx

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap